Dr Chamie on the FDA Approval of N-803 Plus BCG for BCG-Unresponsive NMIBC

Karim Chamie, MD, discusses the FDA approval of nogapendekin alfa plus BCG for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Related Keywords

California ,United States ,Karim Chamie ,Los Angeles ,University Of California ,Bacillus Calmette ,D ,Fda Approval Of Nogapendekin Alfa Plus Bcg ,Patients With Bcg Unresponsive Non Muscle Invasive Bladder Cancer ,